Valneva (VALN) to Release Earnings on Tuesday

Key Points

• Valneva is set to release its Q2 2025 earnings report on August 12th, with analysts predicting a loss of $0.27 per share and revenue of $46.28 million.
• In the previous quarter, Valneva reported a loss of $0.13 per share and revenue of $51.79 million, outperforming estimates of a larger loss.
• Valneva's stock price increased by 2.5%, and the company currently has a market capitalization of approximately $653.92 million.

Valneva (NASDAQ:VALN - Get Free Report) is expected to be releasing its Q2 2025 earnings data before the market opens on Tuesday, August 12th. Analysts expect Valneva to post earnings of ($0.27) per share and revenue of $46.28 million for the quarter.

Valneva (NASDAQ:VALN - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.27. Valneva had a negative net margin of 43.08% and a negative return on equity of 43.05%. The company had revenue of $51.79 million for the quarter, compared to analysts' expectations of $41.80 million. On average, analysts expect Valneva to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Valneva Stock Performance

Valneva stock traded up $0.06 during midday trading on Thursday, reaching $8.25. 99,175 shares of the company's stock were exchanged, compared to its average volume of 52,841. The stock's 50-day simple moving average is $6.41 and its 200 day simple moving average is $6.54. The firm has a market cap of $702.03 million, a price-to-earnings ratio of -6.93 and a beta of 1.77. The company has a debt-to-equity ratio of 0.92, a quick ratio of 2.12 and a current ratio of 2.70. Valneva has a 52 week low of $3.62 and a 52 week high of $8.66.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on VALN. HC Wainwright reiterated a "buy" rating and set a $17.00 target price on shares of Valneva in a research note on Tuesday, April 15th. Guggenheim reduced their price objective on shares of Valneva from $15.00 to $14.00 and set a "buy" rating for the company in a research report on Thursday, May 8th.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.